Table 1 Patient disposition by dose... | American Society of Hematology

Table 1

Patient disposition by dose level in the phase 1 and phase 2 portions, and number of patients experiencing DLT*

Dose level	Lenalidomide dose, mg/d	Bortezomib dose, mg/m²	Dexamethasone dose†, mg	PLD dose, mg/m²	No. of patients enrolled	DLT, n
Phase 1: Dose escalation (n = 40)
1	15	1.3	20	20	4	0
2	20	1.3	20	20	10	2
3	25	1.3	20	20	19	3
4	25	1.3	20	30	7	0
Phase 2: After MTD determination (n = 32)‡
4	25	1.3	30	30	32	NA

Dose level	Lenalidomide dose, mg/d	Bortezomib dose, mg/m²	Dexamethasone dose†, mg	PLD dose, mg/m²	No. of patients enrolled	DLT, n
Phase 1: Dose escalation (n = 40)
1	15	1.3	20	20	4	0
2	20	1.3	20	20	10	2
3	25	1.3	20	20	19	3
4	25	1.3	20	30	7	0
Phase 2: After MTD determination (n = 32)‡
4	25	1.3	30	30	32	NA

NA indicates not applicable.

Two patients were not evaluable for DLT per protocol and were replaced.

20 mg/d dexamethasone cycles 1-4 and 10 mg/d dexamethasone cycles 5-8 and maintenance.

Including 7 patients treated at level 4 (MTD).